After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Earlier in 2019 Sanofi also paid Regeneron $462 million to exit from an immuno-oncology alliance formed in 2015, and in 2017 said they would end discovery research in new antibody drugs.

Goldman Sachs analyst James Quigley upgraded Sanofi (SNYNF – Research Report) to a Hold today and set a price target of €120.00. The company’s ...

NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in first draft guidance, citing uncertainties with evidence.

Regeneron Pharmaceuticals Inc. closed 44.49% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...